Breathe Well Live Well
|
Study reveals new insights into how asthma 'pathways' could be blocked
Medical Xpress Asthma affects about five million people in the UK. Not all patients respond the same way to current treatments, suggesting that asthma is more than a single disease. Drugs that target specific molecules in the lungs suggest that the typical symptoms … |
View full post on asthma – Google News
|
AIR POLLUTION: EPA foes turned asthma study into weapon for ozone fight
Environment & Energy Publishing When a Johns Hopkins University researcher published a study showing race and income as risk factors for asthma, she started getting phone calls from industry groups opposing U.S. EPA's bid to tighten the national ozone standard. Dr. Corinne Keet said … |
View full post on asthma – Google News
|
Police Log: Someone spraying stuff into caller's home to give her asthma attack
NRToday.com 3:03 a.m. — Caller reports suspicious person peeking in his or her windows, walking around the house and spraying stuff to give caller asthma attacks in the 300 block of Surprise Avenue, Canyonville. 3:13 a.m. — Intoxicated man reportedly crawled … |
View full post on asthma – Google News
|
Key Asthma Budget Item Signed Into Law in Missouri
STLtoday.com Medicaid will begin reimbursing Missouri healthcare providers that perform home assessments and asthma education to high-risk children with severe asthma, beginning July 1, 2015. Missouri Governor Jay Nixon approved a $500,000 line item in the state's … |
View full post on asthma – Google News
Wall Street Journal (blog) |
UK Biotech Circassia Moves Into Asthma With Two Acquisitions
Wall Street Journal (blog) Allergy and asthma are natural bedfellows: That's the rationale behind Circassia Pharmaceuticals PLC's acquisition spree announced Friday. The Oxford, England, biotech, which is developing vaccines for a range of allergies, has bought Swedish-listed … UK's Circassia buys two asthma-focused firms for up to $377 million Circassia Pharma buys two asthma-focussed companies Circassia In Share Sale To Fund GBP239 Million In Acquisitions (ALLISS) |
View full post on asthma – Google News
|
When allergies turn into asthma
Reno Gazette Journal Have you had a persistent cough that just won't go away? You feel wheezy and your eyes are watery. If you've never had asthmatic symptoms before, it could be frightening. What you may be experiencing is allergy induced asthma. Many northern Nevadans … |
View full post on asthma – Google News
|
Genetic Mutations in Asthma Come into Question
Genetic Engineering & Biotechnology News Estimates of heritability for asthma sufferers would suggest that nearly half of the variation in risk can be attributed to some type of genetic factor. However, common genetic variants that have been identified by genome-wide association studies (GWAS … Rare mutations do not explain 'missing heritability' in asthma Rare mutations do not explain "missing heritability" in asthma |
View full post on asthma – Google News
Medical News Today |
Link between antibiotics and childhood asthma called into question
Medical News Today Several studies have demonstrated a link between maternal antibiotic use during pregnancy or early childhood antibiotic use and increased risk of the child developing asthma. Though such studies have led to general belief of a causal link, researchers … Causal link between antibiotics and childhood asthma dismissed |
View full post on asthma – Google News
Reuters |
Promising asthma trial prompts Regeneron, Sanofi to push dupilumab into PhIII
FierceBiotech Regeneron and its close partner Sanofi have cleared the final mid-stage hurdle for dupilumab in asthma patients, with several doses hitting the trial endpoint both for a subset of patients as well as the broad population. And the ambitious development … Sanofi's dual-action biotech asthma drug performs well in test Positive results for Sanofi/Regeneron's dupilumab in asthma |
View full post on asthma – Google News
|
AstraZeneca enters into $232m asthma drug deal with Synairgen
Pharmaceutical Business Review AstraZeneca has entered into a global licence agreement with Synairgen for SNG001, a new, inhaled interferon beta (IFN-beta) being developed for the treatment of respiratory tract viral infections in patients with severe asthma. AstraZeneca … |
View full post on asthma – Google News